Australia's Clinuvel Pharmaceuticals soars on positive study results

Clinuvel Pharmaceuticals

05/07/2024 05:09

** Shares of Clinuvel Pharmaceuticals  CUV.AX  rise as much
as 16.7% to A$17.710, posting their biggest intraday pct jump
since Aug 31, 2022
    ** Stock hits highest level since Dec. 11, 2023
    ** Pharmaceutical co announces results of its afamelanotide
study evaluating DNA-repair capacity of afamelanotide on skin of
healthy volunteers exposed to UV radiation
    ** Says results shows afamelanotide can reduce oxidative
damage and inflammatory reactions after sun exposure and skin
damage
    ** Says study shows afamelanotide assists DNA repair after
UV damage
    ** Stock down 5.2% YTD as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))